CVR number 30068440
Industry 46.4610 Wholesale of pharmaceutical goods

VILOVET A/S

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
N/A
2024
2024/12
Bankruptcy risk for industry  1.1% 1.1% 1.1% 1.1% 1.1%  
Bankruptcy risk  3.0% 2.8% 2.1% 0.0% 3.6%  
Credit score (0-100)  57 58 67 0 53  
Credit rating  BBB BBB A N/A BBB  
Credit limit (kDKK)  0.0 0.1 4.9 8,133.8 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
N/A
2024
2024/12
Net sales  0 0 0 0 0  
Gross profit  41,058 41,876 36,093 35,713 36,123  
EBITDA  31,402 31,926 26,013 25,289 25,402  
EBIT  31,358 31,876 25,948 25,289 25,402  
Pre-tax profit (PTP)  31,425.5 31,959.4 26,147.7 26,304.3 26,461.1  
Net earnings  24,498.3 24,919.4 20,383.3 20,502.6 20,627.7  
Pre-tax profit without non-rec. items  31,426 31,959 26,148 25,289 25,402  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
N/A
2024
2024/12
Tangible assets total  40.0 101 188 178 121  
Shareholders equity total  51,628 61,548 61,931 62,434 63,061  
Interest-bearing liabilities  1,214 1,085 779 623 1,046  
Balance sheet total (assets)  103,171 109,505 113,388 132,160 134,515  
Net Debt  1,214 1,085 779 623 1,046  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
N/A
2024
2024/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  41,058 41,876 36,093 35,713 36,123  
Gross profit growth  11.5% 2.0% -13.8% -1.1% 1.1%  
Employees  20 21 18 17 17  
Employee growth %  0.0% 5.0% -14.3% -5.6% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  103,171 109,505 113,388 132,160 134,515  
Balance sheet change%  9.4% 6.1% 3.5% 16.6% 1.8%  
Added value  31,401.9 31,925.9 26,012.7 25,354.7 25,402.3  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -87 11 22 -10 -57  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
N/A
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  76.4% 76.1% 71.9% 70.8% 70.3%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  31.8% 30.1% 23.5% 20.6% 19.1%  
ROI %  65.5% 55.4% 41.8% 40.2% 40.0%  
ROE %  52.3% 44.0% 33.0% 33.0% 32.9%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
N/A
2024
2024/12
Equity ratio %  50.0% 56.2% 54.6% 47.2% 46.9%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  3.9% 3.4% 3.0% 2.5% 4.1%  
Gearing %  2.4% 1.8% 1.3% 1.0% 1.7%  
Net interest  0 0 0 0 0  
Financing costs %  1.2% 1.4% 2.5% 0.0% 0.0%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
N/A
2024
2024/12
Quick Ratio  1.5 1.7 1.7 1.4 1.4  
Current Ratio  2.0 2.3 2.2 1.9 1.9  
Cash and cash equivalent  0.0 0.0 0.0 0.0 0.0  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
N/A
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  51,588.3 61,446.8 61,742.8 62,255.6 62,940.1  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
N/A
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  1,570 1,520 1,445 1,491 1,494  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  1,570 1,520 1,445 1,488 1,494  
EBIT / employee  1,568 1,518 1,442 1,488 1,494  
Net earnings / employee  1,225 1,187 1,132 1,206 1,213